Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung
Conditions
Keywords
lung cancer, non-small cell lung cancer, small cell lung cancer, cancer metabolism
Brief summary
The purpose of this study is to learn more about the metabolic properties of lung cancer cells.
Detailed description
It has long been known that cancer cells absorb and break down substances in the body differently than healthy, non-cancer cells. This process of absorbing and breaking down substances is known as metabolism and is increased in cancer cells. Recent research suggests that this increased metabolic activity makes it easier for cancer cells to multiply. The objective of the study is to characterize the metabolism of glucose by lung tumors by serum metabolite analysis, using a variant of glucose (sugar) which makes up 1% of glucose in nature.
Interventions
OTHER13-C-glucose
10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer.
Sponsors
James Graham Brown Cancer Center
University of Louisville
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Lung Cancer Patients (Groups 1 & 2) Inclusion Criteria: * patients with suspected, clinically diagnosed, or histologically diagnosed lung cancer. Occasionally, other cancers (including metastatic cancers to the lung) may be resected for the study as negative controls for NSCLC, as warranted by the particulars of the case. * patients must have general medical conditions to allow them to undergo surgical resection of their primary tumor
Exclusion criteria
* history of diabetes for the experimental group (surgery + glucose); patients with a history of diabetes are allowed in the control group (surgery/no glucose) * known hepatitis C or HIV (AIDS) Healthy Subjects (Group 3) Inclusion Criteria: * at least 30 years of age * preferably be fasting for 12 hours (minimum 8 hours) prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| metabolic profiles of cancerous vs. healthy lung tissue | after 13-C-glucose infusion |
Secondary
| Measure | Time frame |
|---|---|
| glycolytic metabolism in plasma | before and after 13-C-glucose infusion |
| metabolic markers in urine | collected during surgery |
| metabolic markers in serum | before and after 13-C-glucose infusion |
| metabolic markers in bronchoalveolar fluid | during diagnostic bronchoscopy or during surgery |
| metabolic markers in expired breath | during surgery |
Countries
United States
Outcome results
None listed